Gastrointestinal dysmotility is associated with proton pump inhibitor refractory oesophagitis in patients with systemic sclerosis

被引:2
作者
Alcala-Gonzalez, Luis G. [1 ,2 ]
Guillen-del-Castillo, Alfredo [3 ,4 ]
Aguilar Cayuelas, Ariadna [1 ,2 ]
Barber Caselles, Claudia [1 ,2 ]
Codina-Clavaguera, Claudia [3 ]
Marin Garcia, Antonio [1 ]
Serra, Jordi [1 ,2 ,4 ]
Malagelada, Carolina [1 ,2 ,4 ]
Simeon-Aznar, Carmen P. [3 ]
机构
[1] Vall DHebron Univ Hosp, Dept Digest Dis, Digest Syst Res Unit, Barcelona 08035, Spain
[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
[3] Vall DHebron Univ Hosp, Internal Med Dept, Syst Autoimmune Dis Unit, Barcelona, Spain
[4] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
关键词
scleroderma; systemic; gastroparesis; gastroesophageal reflux; oesophagitis; peptic; intestinal dysmotility; MANOMETRY;
D O I
10.1093/rheumatology/keae481
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Patients with systemic sclerosis present with severe gastroesophageal reflux disease, often refractory to proton-pump inhibitors (PPI) treatment. The aim of the present study was to identify factors associated with PPI-refractory oesophagitis. Methods We performed a cross-sectional study in a single-centre cohort of patients diagnosed with systemic sclerosis. We included patients who underwent an oesophagogastroduodenoscopy while on PPI treatment. Patients with PPI-refractory erosive oesophagitis were compared with those with endoscopically normal oesophageal mucosa. Results A total of 69 patients were included. From these, 23 patients (33%) had PPI-refractory oesophagitis (Grade A, n = 11; Grade B, n = 7; Grade C, n = 2; Grade D, n = 3) and 46 (67%) had an endoscopically normal oesophageal mucosa. On univariate analysis, patients with PPI-refractory oesophagitis were more frequently diffuse SSc subset (43% vs 17%; P = 0.041). Evaluating gastrointestinal motility tests, neither absent oesophageal contractility (39% vs 25%, P = 0.292) nor hypotensive lower oesophageal sphincter (47% vs 44%, P = 0.980) were significantly associated with PPI-refractory oesophagitis. Gastrointestinal dysmotility, defined as abnormal gastric emptying and/or small bowel dilated loops, was significantly associated with PPI-refractory oesophagitis (66 vs 8%, P =<0.001). On a multivariate regression model to evaluate the association between motility test results adjusted for the diffuse subset, gastrointestinal dysmotility (beta = 0.751, P = 0.010) was independently associated with PPI-refractory oesophagitis, while absent oesophageal contractility (beta = 0.044, P = 0.886) or a hypotensive LES were not (beta = -0.131, P = 0.663). Conclusions Our findings suggest that gastric and small intestinal motor dysfunction may be an important contributor to the development of PPI-refractory oesophagitis in patients with systemic sclerosis. Graphical Abstract
引用
收藏
页码:3074 / 3079
页数:6
相关论文
共 20 条
[1]   Gastroparesis in systemic sclerosis: a detailed analysis using whole-gut scintigraphy [J].
Adler, Brittany ;
Hummers, Laura K. ;
Pasricha, P. Jay ;
McMahan, Zsuzsanna H. .
RHEUMATOLOGY, 2022, 61 (11) :4503-4508
[2]   Spectrum of esophageal dysmotility in systemic sclerosis on high-resolution esophageal manometry as defined by Chicago classification [J].
Aggarwal, N. ;
Lopez, R. ;
Gabbard, S. ;
Wadhwa, N. ;
Devaki, P. ;
Thota, P. N. .
DISEASES OF THE ESOPHAGUS, 2017, 30 (12)
[3]  
Alcal-Gonzlez LG., 2023, NEUROGASTROENT MOTIL, V35, pe14643
[4]   Higher risk of neoplastic progression of Barrett's esophagus in patients with systemic sclerosis [J].
Anilkumar, Mythri ;
Alkhayyat, Motasem ;
Grewal, Udhayvir S. ;
Sanaka, Madhusudhan R. ;
Thota, Prashanthi N. .
GASTROENTEROLOGY REPORT, 2021, 9 (06) :595-596
[5]   Pathophysiology of gastro-oesophageal reflux disease: implications for diagnosis and management [J].
Arguero, Julieta ;
Sifrim, Daniel .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (04) :282-293
[6]   A Multinational Survey Investigating the Unmet Needs and Patient Perspectives Concerning Proton Pump Inhibitors in Systemic Sclerosis [J].
Bandini, Giulia ;
Alunno, Alessia ;
Pinheiro, Filipe O. ;
Campochiaro, Corrado ;
Galetti, Ilaria ;
Matucci-Cerinic, Pietro ;
Ruaro, Barbara ;
El Aoufy, Khadija ;
Melis, Maria R. ;
Pignone, Alberto Moggi ;
Randone, Silvia Bellando ;
Dagna, Lorenzo ;
Matucci-Cerinic, Marco ;
Mcmahan, Zsuzsanna H. ;
Hughes, Michael .
ARTHRITIS CARE & RESEARCH, 2024, 76 (05) :608-615
[7]   Significant gastrointestinal unmet needs in patients with Systemic Sclerosis: insights from a large international patient survey [J].
Bandini, Giulia ;
Alunno, Alessia ;
Ruaro, Barbara ;
Galetti, Ilaria ;
Hughes, Michael ;
Mcmahan, Zsuzsanna H. .
RHEUMATOLOGY, 2024, 63 (03) :e92-e93
[8]   Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease [J].
Hughes, Michael ;
Allanore, Yannick ;
Baron, Murray ;
Del Galdo, Francesco ;
Denton, Christopher P. ;
Frech, Tracy ;
Furst, Daniel E. ;
Galetti, Ilaria ;
Dagna, Lorenzo ;
Herrick, Ariane L. ;
Kuwana, Masataka ;
Matucci-Cerinic, Pietro ;
McMahan, Zsuzsanna H. ;
Murray, Charles D. ;
Proudman, Susanna ;
Matucci-Cerinic, Marco .
LANCET RHEUMATOLOGY, 2022, 4 (11) :E794-E802
[9]   Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification [J].
Lundell, LR ;
Dent, J ;
Bennett, JR ;
Blum, AL ;
Armstrong, D ;
Galmiche, JP ;
Johnson, F ;
Hongo, M ;
Richter, JE ;
Spechler, SJ ;
Tytgat, GNJ ;
Wallin, L .
GUT, 1999, 45 (02) :172-180
[10]   Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy [J].
Marie, I. ;
Ducrotte, P. ;
Denis, P. ;
Hellot, M. F. ;
Levesque, H. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (11-12) :1593-1601